Essay examines tensions in longevity between improving healthspan with basic care and pursuing radical biological and technological augmentation, highlighting equity and social questions as AI and BCIs converge with the field.
Key Takeaways
- Public figures Bryan Johnson and David Sinclair are portrayed as advocating moves from
- Article cites a 14.6-year life expectancy gap between richest and poorest US populations
- Typical longevity programs currently cost roughly $20K–$40K per year while advanced therapies